Serina Therapeutics Showcases Innovations at the Injectables Summit
Innovation in Drug Delivery at the Injectables Summit
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER) is making waves in the biotechnology field with its groundbreaking POZ Platform technology. This innovative drug delivery method aims to improve the lives of patients suffering from neurological diseases. At a recent prestigious event, the 14th Annual Injectables Summit, Serina's Chief Development Officer, Randall Moreadith, MD, PhD, took the stage alongside Enable Injections’ Chief Commercial Officer, Matthew Huddleston, to present their collaborative efforts in advancing patient care.
Collaboration for Advanced Parkinson's Disease
The joint presentation titled, “Patient-enabled Therapy for Advanced Parkinson's Disease - A Case Study with Serina Therapeutics' SER-252 + Enable Injections' enFuse Wearable Drug Delivery Platform” highlighted how both companies are working together to develop effective and patient-friendly therapeutics. Their unique approach focuses on enhancing drug delivery methods that are both comfortable and convenient for those living with advanced Parkinson's Disease, aiming to significantly improve the quality of life for these individuals.
About Serina Therapeutics and Its Mission
Serina is dedicated to developing a range of proprietary drug product candidates, targeting neurological diseases and other significant health issues. The company's POZ Platform technology is not only innovative but holds great promise for the future of drug delivery. This cutting-edge platform aims to enhance the efficacy and safety of various treatment modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs), paving the way for potentially transformative therapies.
Headquarters and Future Vision
Located on the campus of the HudsonAlpha Institute of Biotechnology in Huntsville, Alabama, Serina operates in a thriving environment conducive to innovation and scientific advancement. The organization emphasizes research and development to drive its vision forward, focusing on unlocking new potentials in drug delivery and treatment efficacy.
Contact Information for Inquiries
For anyone interested in learning more about Serina Therapeutics or their current projects, inquiries can be directed to their investor relations team. They can be reached via email at Investor.relations@serinatherapeutics.com or by phone at (256) 327-9630.
Frequently Asked Questions
What is the POZ Platform technology?
The POZ Platform is a proprietary drug delivery technology developed by Serina Therapeutics that aims to enhance the efficacy and safety of various therapeutic modalities.
Who presented at the Injectables Summit?
Randall Moreadith, MD, PhD, from Serina Therapeutics and Matthew Huddleston from Enable Injections collaborated on a presentation about advanced Parkinson's disease.
What is the focus of Serina Therapeutics?
Serina Therapeutics focuses on developing drug products targeting neurological diseases and improving therapeutic delivery methods.
Where is Serina Therapeutics based?
Serina Therapeutics is located in Huntsville, Alabama, at the HudsonAlpha Institute of Biotechnology.
How can I contact Serina Therapeutics?
You can contact Serina Therapeutics via email at Investor.relations@serinatherapeutics.com or by calling (256) 327-9630.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.